GW has been selected as one of about 90 sites to participate in clinical trials of experimental vaccines and monoclonal antibodies as part of the COVID-19 Prevention Network, established by the National Institute of Allergy and Infectious Diseases.
The summit provided an international audience of patients and health care professionals with information on the latest developments and trends around patient care, especially in relation to the COVID-19 pandemic.
